Ceritinib is an Orally Active ALK Tyrosine Kinase Inhibitor for Kinds of Cancers Research
Ceritinib is an orally active ALK tyrosine kinase inhibitor for kinds of cancers research.
Ceritinib is an orally active ALK tyrosine kinase inhibitor for kinds of cancers research.
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase of insulin receptor superfamily. In addition, ALK is relevant with solid and hematologic cancers, such as none small cell lung cancers…
On November 16, 2023, the U.S. Food and Drug Administration has approved Repotrectinib. Repotrectinib is indicated for the treatment of adult patients with ROS1-positive locally advanced or metastatic non-small cell…
ROS1 (c-ros oncogene 1) is a receptor tyrosine kinase encoded by the gene ROS1. Importantly, ROS1 is a proto-oncogene and highly expressed in a variety of tumor cell lines, belonging…
Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause that occurs primarily in older adults. In addition, IPF is characterized by substantial…
Repotrectinib is a potent ROS1 (IC50=0.07 nM) and TRK (IC50=0.83/0.05/0.1 nM for TRKA/B/C) inhibitor. The IC50 values are 0.83/0.05/0.1 nM for TRKA/B/C, respectively. Repotrectinib potently inhibits WT ALK (IC50=1.01 nM). Repotrectinib inhibits mutant ALKs. It inhibits…
In this article, we will introduce an orally bioavailable, ATP-competitive ALK and c-Met inhibitor, Crizotinib. The IC50 values for ALK and c-Met kinases are 20 and 8 nM, respectively. Additionally, in cell-based assays, Crizotinib…
Fibrodysplasia ossificans progressiva (FOP) is a congenital disorder of progressive. It is widespread postnatal ossification of soft tissues and is without known effective treatments. A recent study identified heterozygous mutations…
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase belonging to the insulin receptor (IR) kinase superfamily. It highly expresses in adult brain tissue and exerts an important role in…
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase. ALK is an attractive target for cancer therapies not only for its prominent role in a number of malignancies but also…